Arkolith/Insider Trading/LENZ/Form 4

Schimmelpennink Evert B.

President, CEO and Secretary, DirectorLENZ Therapeutics, Inc. (LENZ) · full profile →Form 4 · filed Jul 23, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 22, 2024Option exercise(M)45K$1.04$47K45K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 22, 2024Option exercise(M)45K—$0342K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001815776-24-000051) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML